Le Lézard
Classified in: Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Apollo Endosurgery, Inc. to Report Second Quarter Results on July 23, 2019


Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the first quarter ended June 30, 2019 on Tuesday, July 23, 2019, after the U.S. stock markets close.

Apollo will hold a conference call on Tuesday, July 23, 2019 at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. The dial-in numbers are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers. The conference ID number is 3369396. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.apolloendo.com.

A replay of the webcast will be made available on Apollo's website, www.apolloendo.com, shortly after completion of the call.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal defect repairs to the interventional treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 70 countries today and include the OverStitchtm Endoscopic Suturing System, the OverStitch Sxtm Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.

Apollo's common stock is traded on Nasdaq Global Market under the symbol "APEN". For more information regarding Apollo Endosurgery, go to: www.apolloendo.com.


These press releases may also interest you

at 02:45
ASE Technology Holding Co., Ltd. (TWSE: 3711, NYSE: ASX) ("We", "ASEH", or the "Company"), the leading provider of semiconductor assembly and testing services ("ATM") and the provider of electronic manufacturing services ("EMS"), today reported its...

at 02:39
MYTILINEOS Energy & Metals (RIC: MYTr.AT) (Bloomberg: MYTIL.GA) announces its Q1 2024 financial results. 10% increase in Net Profit after minorities to ?158 million vs. ?143 million in Q1 2023. Earnings per Share came in at ?1.141, an increase of...

at 02:30
Allied Market Research published a report, titled, "Pension Administration Software Market by Component (Solution and Services), Deployment Mode (On-Premise and Cloud), Type (Public Pension and Private Pension), End User (Employers, Pension Plan...

at 02:26
Having consistently outperformed its targets and strategic goals, MYTILINEOS Energy & Metals ("MYTILINEOS") has initiated a review and evaluation of its strategic options, in consultation with its financial, legal and tax...

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...



News published on and distributed by: